Skip to main content
Be The Investor
S&P 500
7,662.54-1.22%
After Hours7,660.80-0.02%
Nasdaq Composite
26,008.86-2.60%
After Hours26,049.24+0.16%
Dow Jones
52,867.98+0.02%
After Hours52,777.32-0.17%
Russell 2000
2,784.03+0.11%
After Hours2,780.44-0.13%
VIX
VIX
19.03+14.09%
Bitcoin
81,792.78+0.59%
Ethereum
2,409.35+0.97%
Solana
104.46+0.88%
Gold
4,031.20-0.72%
Silver
54.21-1.45%
Copper
6.421+0.35%
WTI Crude Oil
99.93+0.46%
US 10-Year Treasury Yield
4.952-3.77%
Home›Stocks›ANAB
OverviewChartNewsFinancialsBusiness ModelCompetitorsStatisticsAnalysisEarningsValuationHoldersOptionsInsidersForecastCompareFAQ
ANAB

AnaptysBio, Inc.

ANAB
NASDAQUnited States flagUSReal-Time Price
$48.10USD
+0.16 (+0.33%)Today
$48.10+0.00 (+0.00%)After Hours7:30 PM ET
BTI Score

BASIC required or higher

View pricing
BTI Fair Market Cap
$2.06B
-30.28% vs fair
Biotechnology
Buy

AnaptysBio, Inc. (ANAB) Valuation

Is AnaptysBio, Inc. (ANAB) overvalued or undervalued? BTI's fair-value estimate, DCF model and valuation multiples show the premium or discount to intrinsic worth.

Valuation Snapshot

P/E (TTM)
Trailing Price-to-Earnings
7.28
Forward P/E
Next 12 months estimate
49.51
PEG Ratio
P/E to Growth ratio
—
Price / Sales
Market cap vs. revenue
—
Price / Book
Market cap vs. book value
—
EV / EBITDA
Enterprise value multiple
—
Earnings Yield
Inverse of P/E
13.74%
Revenue Growth
Year-over-year
—

Valuation Risk

AnaptysBio, Inc.'s valuation multiples are within a moderate range, suggesting the market is not pricing in excessive optimism. Investors should monitor growth execution relative to valuation.

Run Full Valuation Model
DCF, multiples, scenario analysis and AI fair value for ANAB